LAWRENCEVILLE, N.J., Dec. 14, 2015 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced the presentation of results from its ongoing Phase I/II US DIGNITY Study of ThermoDox® in combination with mild hyperthermia in patients with recurrent chest wall (RCW) breast cancer. The data, which demonstrated a combined local response rate of 61.9% among evaluable patients treated with ThermoDox®, were presented onSaturday, December 12, 2015 at the San Antonio Breast Cancer Symposium during a poster session titled New Drugs and Treatment Strategies. Celsion Corporation is a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies for the treatment of cancer and other difficult-to-treat diseases.

"Results from this study are very encouraging and suggest that ThermoDox® combined with superficial hyperthermia offers a promising and well tolerated treatment option for patients with recurrent chest wall disease from breast cancer, a highly refractory form of breast cancer associated with poor quality of life and limited treatment options," said Hope Rugo, M.D., Clinical Professor, Department of Medicine and Director, Breast Oncology Clinical Trials Program at the University of California, San Francisco, and lead investigator of the study. "These findings underscore the potential for this therapy to serve as a much needed treatment for these patients, and further define the importance of advancing development of ThermoDox® in this indication," Dr. Rugo added.

In the Phase I/II trials, which were designed to evaluate the safety and anti-tumor activity of ThermoDox® in combination with mild hyperthermia in RCW breast cancer, a total of 28 patients were treated at doses of either 40 or 50 mg/m2. In addition to a local response rate of 61.9% among evaluable patients, a combined local response rate was observed in 46.4% of the intent-to-treat population (13/28), notably consisting of five patients demonstrating a durable local response lasting greater than three months, including four complete responses (CR) and one partial response (PR). Patients dosed at 40 mg/m2 displayed a comparable response rate and a more favorable safety profile to that of patients receiving 50 mg/m2. As a result, 40 mg/m2 will be the recommended dose for future clinical trials in this indication.
"ThermoDox® in RCW breast cancer continues to yield striking response data in this vulnerable patient population, further validating our commitment to expanding this program, including the initiation of the Euro-DIGNITY Trial, a multi-center study designed to evaluate ThermoDox's potential to locally control chest wall lesions in earlier-stage patients," said Michael H. Tardugno, Celsion's chairman, president and CEO. "Additionally, we remain committed to providing patients who are suffering from this aggressive form of breast cancer with access to ThermoDox®, and are continuing to work closely with myTomorrows to ensure the success of our Early Access Program in Europe for ThermoDox® in RCW breast cancer."

More HCB News